Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

September 25, 2018

Study Completion Date

May 26, 2022

Conditions
Resectable Pancreatic Cancer
Interventions
DRUG

Doxycycline

Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.

Trial Locations (1)

53226

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT02775695 - Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter